- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma
This study looks at new treatments for a type of blood cancer called mantle cell lymphoma that has come back or hasn't responded to earlier treatments. We're comparing a drug named Ibrutinib with standard treatments like Lenalidomide or Bortezomib, all given with Rituximab, to see which works best.
For: Relapsed/Refractory Mantle Cell LymphomaCzechia · Spain · Poland - Enrolling by invitationPHASE1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
This study helps us understand the long-term safety of new treatments for certain cancers like leukemia and lymphoma. People who have already been in an earlier drug trial for these conditions will continue to be monitored to see how they respond over time.
For: Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-HodgkinBelgium · France · Georgia